Drug intelligence / Profile preview

FPT-20

Development stage: Phase 1
Lead developer: Trieu
Modality: Small Molecules
Administration: Oral

Overview

FPT-20 is a natural flavonoid-based formulation developed by Dr. Nguyen Thi Trieu for the treatment of male infertility and orchitis. The product is designed to eliminate inflammatory tissue and promote the regeneration of testicular structures, including the lobules, tubule epithelium, and connective tissue. By restoring the function of Leydig and Sertoli cells, FPT-20 aims to re-establish spermatogenesis in patients where the process was halted due to chronic inflammation or tissue damage. It is currently being evaluated in Phase 4 clinical trials for its efficacy in improving sperm production and treating semen disorders.

Targets

HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HTR1B (5-Hydroxytryptamine Receptor 1B)HTR1D (5-hydroxytryptamine receptor 1D)

Beyond the preview

Go deeper on FPT-20.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FPT-20.

Explore the full profile